HIV-related comorbidities appear to be related to chronic inflammation, a condition characterizing people living with HIV (PLWH). Prior work indicates that cannabidiol (CBD) might reduce inflammation; however, the genetics underpinning of this effect are not well investigated. Our main objective is to detect gene expression alterations in human peripheral blood mononuclear cells (PBMCs) from PLWH after at least 1 month of CBD treatment.
Materials and Methods:
We analyzed ∼41,000 PBMCs from three PLWH at baseline and after CBD treatment (27–60 days) through single-cell RNA sequencing.
Results:
We obtained a coherent signature, characterized by an anti-inflammatory activity, of differentially expressed genes in myeloid cells.
Conclusions:
Our study shows how CBD is associated with alterations of gene expression in myeloid cells after CBD treatment. Clinical Trial Registration: NCT05209867.
Get full access to this article
View all access options for this article.
References
1.
NasiM, De BiasiS, GibelliniL, et al.Ageing and inflammation in patients with HIV infection. Clin Exp Immunol, 2017; 187(1):44–52; doi: 10.1111/cei.12814
2.
FerrucciL, FabbriE. Inflammageing: Chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol, 2018; 15(9):505–522; doi: 10.1038/s41569-018-0064-2
3.
AndradeVM, MavianC, BabicD, et al.A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption. Proc Natl Acad Sci U S A, 2020; 117(18):9981–9990; doi: 10.1073/pnas.1917034117
4.
VignolesM, AndradeV, NogueraM, et al.Persistent HIV-1 transcription in CD4+ T cells from ART-suppressed individuals can originate from biologically competent proviruses. J Virus Erad, 2021; 7(3):100053; doi: 10.1016/j.jve.2021.100053
5.
HendricksCM, CashMN, TagliamonteMS, et al.Discordance between HIV-1 population in plasma at rebound after structured treatment interruption and archived provirus population in peripheral blood mononuclear cells. Microbiol Spectr, 2022; 10(4):e01353-22; doi: 10.1128/spectrum.01353-22
6.
PalmerS, MaldarelliF, WiegandA, et al.Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A, 2008; 105(10):3879–3884; doi: 10.1073/pnas.0800050105
7.
EiseleE, SilicianoRF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity, 2012; 37(3):377–388; doi: 10.1016/j.immuni.2012.08.010
8.
StevensonM. Role of myeloid cells in HIV-1-host interplay. J Neurovirol, 2015; 21(3):242–248; doi: 10.1007/s13365-014-0281-3
9.
RodriguesV, RuffinN, San-RomanM, ETAL. Myeloid cell interaction with HIV: A complex relationship. Front Immunol, 2017; 8:1698; doi: 10.3389/fimmu.2017.01698
10.
WongME, JaworowskiA, HearpsAC. The HIV reservoir in monocytes and macrophages. Front Immunol, 2019; 10:1435; doi: 10.3389/fimmu.2019.01435.
11.
MerinoKM, AllersC, DidierES, ETAL. Role of monocyte/macrophages during HIV/SIV infection in adult and pediatric acquired immune deficiency syndrome. Front Immunol, 2017; 8:1693; doi: 10.3389/fimmu.2017.01693
12.
LiangH, XieZ, ShenT. Monocyte activation and cardiovascular disease in HIV infection. Cell Mol Immunol, 2017; 14(12):960–962; doi: 10.1038/cmi.2017.109
13.
MariniE, TiberioL, CaraccioloS, et al.HIV-1 matrix protein p17 binds to monocytes and selectively stimulates MCP-1 secretion: Role of transcriptional factor AP-1. Cell Microbiol, 2008; 10(3):655–666; doi: 10.1111/j.1462-5822.2007.01073.x
14.
TenorioAR, ZhengY, BoschRJ, et al.Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis, 2014; 210(8):1248–1259; doi: 10.1093/infdis/jiu254
15.
HuntPW, SinclairE, RodriguezB, et al.Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis, 2014; 210(8):1228–1238; doi: 10.1093/infdis/jiu238
16.
RodésB, CadiñanosJ, Esteban-CantosA, ETAL. Ageing with HIV: Challenges and biomarkers. Ebiomedicine, 2022; 77:103896; doi: 10.1016/j.ebiom.2022.103896
17.
HurdYL, YoonM, ManiniAF, ETAL. Early phase in the development of cannabidiol as a treatment for addiction: Opioid relapse takes initial center stage. Neurotherapeutics, 2015; 12:807–815; doi: 10.1007/s13311-015-0373-7
18.
AstrayG, MejutoJC, XiaoJ, et al.Benefits, toxicity and current market of cannabidiol in edibles. Crit Rev Food Sci Nutr, 2021:1–3; doi: 10.1080/10408398.2021.2024493
19.
AtalayS, Jarocka-KarpowiczI, SkrzydlewskaE. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants, 2020; 9(1):21; doi: 10.3390/antiox9010021
20.
SundaF, ArowoloA. A molecular basis for the anti-inflammatory and anti-fibrosis properties of cannabidiol. FASEB J, 2020; 34(11):14083–14092; doi: 10.1096/fj.202000975R
21.
BursteinS. Cannabidiol (CBD) and its analogs: A review of their effects on inflammation. Bioorg Med Chem, 2015; 23(7):1377–1385; doi: 10.1016/j.bmc.2015.01.059
22.
CostiniukCT, JenabianMA. Cannabinoids and inflammation: Implications for people living with HIV. AIDS, 2019; 33(15):2273–2288; doi: 10.1097/QAD.0000000000002345
23.
HaoY, HaoS, Andersen-NissenE, et al.Integrated analysis of multimodal single-cell data. Cell, 2021; 184(13):3573.e29–3587.e29; doi: 10.1016/j.cell.2021.04.048
24.
SzklarczykD, GableAL, NastouKC, et al.The STRING database in 2021: Customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res, 2021; 49(D1):D605–D612; doi: 10.1093/nar/gkaa1074
25.
JinS, Guerrero-JuarezCF, ZhangL, et al.Inference and analysis of cell-cell communication using CellChat. Nat Commun, 2021; 12(1):1088; doi: 10.1038/s41467-021-21246-9
26.
RussoRC, GarciaCC, TeixeiraMM, et al.The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev Clin Immunol, 2014; 10(5):593–619; doi: 10.1586/1744666X.2014.894886
27.
VermaV, KhouryS, ParisienM, et al.The dichotomous role of epiregulin in pain. Pain, 2020; 161(5):1052–1064; doi: 10.1097/j.pain.0000000000001792
28.
VeenhuisRT, AbreuCM, ShirkEN, et al.HIV replication and latency in monocytes and macrophages. Semin Immunol, 2021; 51:101472; doi: 10.1016/j.smim.2021.101472
29.
RenouxF, StellatoM, HaftmannC, et al.The AP1 transcription factor Fosl2 promotes systemic autoimmunity and inflammation by repressing Treg development. Cell Rep, 2020; 31(13):107826; doi: 10.1016/j.celrep.2020.107826
30.
LiuN, JiangC, CaiP, et al.Single-cell analysis of COVID-19, sepsis, and HIV infection reveals hyperinflammatory and immunosuppressive signatures in monocytes. Cell Rep, 2021; 37(1):109793; doi: 10.1016/j.celrep.2021.109793
31.
Blondin-LadrieL, FourcadeL, ModicaA, et al.Monocyte gene and molecular expression profiles suggest distinct effector and regulatory functions in Beninese HIV highly exposed seronegative female commercial sex workers. Viruses, 2022; 14(2):361; doi: 10.3390/v14020361
32.
FooCX, BartlettS, ChewKY, et al.GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection. Eur Respir J, 2023; 61(3):2201306; doi: 10.1183/13993003.01306-2022
33.
BoucherA, KlopfensteinN, HallasWM, et al.The miR-23a∼27a∼24-2 microRNA cluster promotes inflammatory polarization of macrophages. J Immunol, 2021; 206(3):540–553; doi: 10.4049/jimmunol.1901277
34.
WuF, ZikusokaM, TrindadeA, et al.MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2α. Gastroenterology, 2008; 135(5):1624.e24–1635.e24; doi: 10.1053/j.gastro.2008.07.068
AudritoV, MessanaVG, DeaglioS. NAMPT and NAPRT: Two metabolic enzymes with key roles in inflammation. Front Oncol, 2020; 10:358; doi: 10.3389/fonc.2020.00358
37.
RenK, TorresR. Role of interleukin-1β during pain and inflammation. Brain Res Rev, 2009; 60(1):57–64; doi: 10.1016/j.brainresrev.2008.12.020
38.
Henao-MejiaJ, ElinavE, StrowigT, et al.Inflammasomes: Far beyond inflammation. Nat Immunol, 2012; 13(4):321–324; doi: 10.1038/ni.2257
CouperKN, BlountDG, RileyEM. IL-10: The master regulator of immunity to infection. J Immunol, 2008; 180(9):5771–5777; doi: 10.4049/jimmunol.180.9.5771
43.
SparrowE, Bodman-SmithMD. Granulysin: The attractive side of a natural born killer. Immunol Lett, 2020; 217:126–132; doi: 10.1016/j.imlet.2019.11.005
44.
WangXM, ZhangJY, XingX, et al.Global transcriptomic characterization of T cells in individuals with chronic HIV-1 infection. Cell Discov, 2022; 8(1):1–17; doi: 10.1038/s41421-021-00367-x
45.
PauliCS, ConroyM, Vanden HeuvelBD, et al.Cannabidiol drugs clinical trial outcomes and adverse effects. Front Pharmacol, 2020; 11:63; doi: 10.3389/fphar.2020.00063
46.
PowisG, MeuilletEJ, IndarteM, et al.Pleckstrin Homology [PH] domain, structure, mechanism, and contribution to human disease. Biomed Pharmacother, 2023; 165:115024; doi: 10.1016/j.biopha.2023.115024
47.
VictorB, HagerK, StacyS. Re-legalizing cannabis for medical use in the USA. J Public Health, 2022; 44(3):679–684; doi: 10.1093/pubmed/fdab066
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
